Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership

Third-party funding will cover the facility’s construction without issuing shares or adding debt to Callan JMB’s balance sheet.

Rhea-AI Summary

Callan JMB (CJMB) expects to break ground on its IV bag manufacturing and distribution facility before the end of October 2026. The $16 million facility at the Atlas Complex in Marion, Alabama, will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership that will not add debt to Callan JMB’s balance sheet. Formal approval of the construction blueprints has been obtained.

The company projects $450 million in annual revenue once construction is complete and the facility becomes fully operational, comprising $300 million from standard intravenous (IV) bags and $150 million from premixed drug IV bags. Planned within the Marion 9 Biomanufacturing Center, the facility advances Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University.

3 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.$16 million facility will be fully third-party funded without dilution, interest or added company debt. 4.7× market cap
• Major point. Forward-looking: it has not happened yet and may not happen.$450 million annual revenue projected when fully operational: $300 million standard IV bags, $150 million premixed drug IV bags.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Blueprint approval completed; Callan JMB expects groundbreaking before the end of October 2026.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Revenue projection depends on completed construction and full operations; the facility is not yet built.

Argus 15 min delay 96 alerts

-10.93% vs previous close $0.45 last price 12644.0x rel. volume Open Argus

Details

Market move: CJMB -10.93% vs previous close. IV bag facility partnership

$0.43 – $0.92 Day Range

$3.02M Mkt Cap at Last Price

On Oct 22, the day this news came out, the latest delayed price for CJMB is 10.93% below the previous close. Our momentum scanner has recorded 96 alerts for this stock so far that day. The latest delayed price is $0.45. Relative volume is exceptionally heavy at 12644.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Third-party facility funding: $16 million Projected annual facility revenue: $450 million Standard IV bag revenue: $300 million +2 more

Third-party facility funding

$16 million

Non-dilutive and non-interest-bearing partnership

Projected annual facility revenue

$450 million

Once construction is complete and the facility is fully operational

Standard IV bag revenue

$300 million

Projected annual revenue component

Premixed drug IV bag revenue

$150 million

Projected annual revenue component

Expected construction start

Before the end of October

Company expects to break ground

Key Terms

non-dilutive, non-interest-bearing, qa/qc

3 terms

non-dilutive financial

"The non-dilutive $16 million capital investment from a third party"

Non-dilutive describes funding or income that does not reduce existing shareholders’ ownership percentage. It matters to investors because it lets a company raise money or generate value—through grants, loans, licensing deals, or revenue—without issuing extra shares, so each existing share keeps the same claim on profits and control; think of adding toppings to a cake without cutting it into more slices.

non-interest-bearing financial

"through a non-dilutive, non-interest-bearing partnership"

Describes a financial instrument, bank account, loan, payable or other obligation that does not pay or accrue explicit interest over its life; holders receive no periodic interest payments and issuers record no interest expense tied to the instrument. Non-interest-bearing items are often short-term or due on demand (for example certain trade payables or short-term notes), but may still carry implicit costs—such as opportunity cost, inflation erosion or, in some accounting and tax regimes, an imputed interest component that must be recognized even though no cash interest is paid.

qa/qc technical

"quality assurance and quality control (QA/QC)"

QA/QC stands for Quality Assurance and Quality Control, processes used to ensure products or services meet certain standards. Think of it as a way to check that a product is safe and works properly before reaching consumers, similar to how a chef tastes food before serving it. For investors, strong QA/QC practices indicate a company's commitment to delivering reliable, high-quality offerings, reducing risks and building trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness

SPRING BRANCH, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today is providing shareholders with a timeline to break ground on an intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. The $16 million facility will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership.

The Company recently announced formal approval of blueprints for the construction and expects to break ground before the end of October. Once the construction is complete and the facility becomes fully operational, it is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.

The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and demonstrates Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University. The blueprint approval significantly advanced the project and provided the design basis to break ground to construct a state-of-the-art facility combining automated production with quality-control and advanced distribution capabilities.

“Achieving blueprint approval was a critical milestone, and we are moving quickly to break ground and begin construction on the facility this month. This facility is backed fully by a third-party investment that will not add debt to Callan JMB’s balance sheet nor is dilutive to Callan JMB shareholders. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness,” said Wayne Williams, Callan JMB's Chief Executive Officer.

About Callan JMB Inc.

Callan JMB Inc. (NASDAQ: CJMB) is a diversified logistics, preparedness, and critical-infrastructure company supporting healthcare organizations, government agencies, and commercial partners. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, and emergency-preparedness services designed to protect critical products, strengthen supply chains, and support continuity of operations. Through its businesses and strategic partnerships, Callan JMB is building a broader platform spanning healthcare and pharmaceutical logistics, domestic manufacturing, and critical electrical infrastructure. For more information, visit www.callanjmb.com.

Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

Media Contact
Arian Hopkins
ahopkins@callanjmb.com

About the Atlas Complex by Callan JMB

Atlas Complex by Callan JMB is a pharmaceutical, medical, and logistics campus located in Marion, Alabama. Designed to support U.S. pharmaceutical onshoring and strengthen domestic supply chains, the campus provides scalable infrastructure for pharmaceutical manufacturing, quality assurance and quality control (QA/QC), research collaboration, workforce development, cold chain logistics, and domestic distribution within a single integrated environment.

Atlas Complex Media Contact
Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by, or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How will Callan JMB fund its Alabama IV bag facility?

The $16 million facility will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership. The funding will not add debt to Callan JMB’s balance sheet.

How much annual revenue does Callan JMB project from the IV bag facility?

Callan JMB projects $450 million in annual revenue once construction is complete and the facility becomes fully operational. That projection includes $300 million from standard IV bags and $150 million from premixed drug IV bags.